Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a single site, double-blind, randomized, placebo-controlled, crossover study to
assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy,
opioid-experienced, non-treatment-seeking subjects.